Insider Transactions in Q1 2023 at Bio Xcel Therapeutics, Inc. (BTAI)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 21
2023
|
Vimal Mehta CEO and President |
SELL
Open market or private sale
|
Direct |
30,000
-34.38%
|
$570,000
$19.93 P/Share
|
|
Mar 21
2023
|
Vimal Mehta CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+39.53%
|
$0
$0.41 P/Share
|
|
Mar 20
2023
|
Vimal Mehta CEO and President |
SELL
Open market or private sale
|
Direct |
34,500
-23.11%
|
$621,000
$18.54 P/Share
|
|
Mar 20
2023
|
Vimal Mehta CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+37.32%
|
$0
$0.41 P/Share
|
|
Mar 15
2023
|
Vincent O'Neill Officer |
SELL
Open market or private sale
|
Direct |
845
-40.55%
|
$16,055
$19.7 P/Share
|
|
Mar 15
2023
|
Frank Yocca Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
985
-9.4%
|
$18,715
$19.69 P/Share
|
|
Mar 15
2023
|
Richard I Steinhart Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,084
-58.15%
|
$39,596
$19.5 P/Share
|
|
Mar 15
2023
|
Javier Rodriguez Officer |
SELL
Open market or private sale
|
Direct |
950
-45.56%
|
$18,050
$19.62 P/Share
|
|
Mar 14
2023
|
Vincent O'Neill Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,084
+50.0%
|
-
|
|
Mar 14
2023
|
Vimal Mehta CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
10,437
+33.85%
|
-
|
|
Mar 14
2023
|
Frank Yocca Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,084
+16.59%
|
-
|
|
Mar 14
2023
|
Richard I Steinhart Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,084
+36.77%
|
-
|
|
Mar 14
2023
|
Javier Rodriguez Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,084
+50.0%
|
-
|
|
Jan 20
2023
|
Vincent O'Neill Officer |
SELL
Open market or private sale
|
Direct |
29,713
-100.0%
|
$891,390
$30.0 P/Share
|
|
Jan 20
2023
|
Vincent O'Neill Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
29,713
+50.0%
|
$0
$0.41 P/Share
|
|
Jan 20
2023
|
Frank Yocca Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
50,000
-85.62%
|
$1,500,000
$30.0 P/Share
|
|
Jan 05
2023
|
Krishnan Nandabalan Director |
SELL
Open market or private sale
|
Direct |
25,889
-98.45%
|
$569,558
$22.63 P/Share
|
|
Jan 05
2023
|
Krishnan Nandabalan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,889
+50.0%
|
$0
$0.41 P/Share
|
|
Jan 04
2023
|
Krishnan Nandabalan Director |
SELL
Open market or private sale
|
Direct |
34,111
-85.6%
|
$716,331
$21.9 P/Share
|
|
Jan 04
2023
|
Krishnan Nandabalan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
34,111
+50.0%
|
$0
$0.41 P/Share
|